The FDA on June 23, 2025, granted accelerated approval to DATROWAY® for adults with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR)-mutated Non-Small Cell Lung Cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. DATROWAY® is a product of Daiichi Sankyo, Inc.
Bottom Ad
Advertisement
Subscribe
